Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016.
|Third Quarter (2019-07-01 – 2019-09-30)|
|First Nine Months of the Year (2019-01-01 – 2019-09-30)|
Group earnings per share: period result divided by a number of 23 157 178 shares (on 2019-09-30). Solidity: equity divided by assets.
Business highlights in Q3 2019
Significant events after this reporting period
Comments from the CEO
A major focus for for Initiator Pharma during the third quarter of 2019 has been the Phase 2a Proof-of-concept trial. Following the succefull completion of the Phase 1 clinical trial in healthy subjects in June 2019 the first patients of the phase 2a trial were dosed in July. While the recruitment of egible patinets has taken slighliy longer than anticipated we are confident that we will be able to report top-line results from the study before year-end.
Another focus for the Company has been the preparation of the IP2018 clinical trial application. We intend to finalize the application and submit it to regulatory authorities during quarter 1, 2020. The filing of the CTA will enable us to exercise the option agreement that we have for this asset with Saniona. This will significantly strenghten the Initiator Pharma pipeline.
For more information, please contact
Claus Olesen, CEO, Initiator Pharma, Mobile: +45-61 26 00 35, E-mail: firstname.lastname@example.org
Torgeir Vaage, CFO, Initiator Pharma, Mobile: +47-924 05 235, E-mail: email@example.com
About Initiator Pharma
Initiator Pharma A/S is a Danish biotechnology company focusing on the development of innovative drugs, targeting key unmet medical needs within the central and peripheral nervous system. Our research is focusing on monoamine reuptake inhibitors, molecules that are affecting the synaptic concentrations of neurotransmitters such as dopamine, serotonin and noradrenaline. Our lead drug candidate, IPED2015 is targeting the medical condition Erectile Dysfunction (ED), and specifically patients with ED that are non-responsive to drugs within the PDE5i class, including the approved drugs ViagraÓ, CialisÓ and LevitraÓ.
Initiator Pharma is based in Aarhus, Denmark. Initiator Pharma is listed on Spotlight Stock Market and has about 3.500 shareholders. Read more at www.initiatorpharma.com.